

# AMR Exclusive: New Innovations in Microbome-Targeted Products

*Author and Scientific Director from Da Volterra Presents Insight at 19TH Annual Superbugs Summit*

LONDON, ENGLAND, UNITED KINGDOM, January 23, 2017 /EINPresswire.com/ -- Innovative approaches to antibiotic drug discovery will be presented by industry expert Jean de Gunzberg, through new updates on microbome-target products at SMI's 19th annual [Superbugs & Superdrugs](#) show when it returns to Central London this spring.

The established Superbugs event set to take place on 20th & 21st March 2017, will once again gather an international audience of scientific leaders, government bodies and anti-infective specialists, to discuss new clinical and industry advances towards fighting antimicrobial resistance (AMR).

Jean de Gunzburg is the Chief Scientific Officer of Da Volterra, an emerging French biotechnology company committed to the discovery and development of innovative approaches to control the deleterious consequences of antibiotic treatments.


“

Economic initiatives ensuring that such R&D projects are sustainable for pharma must be put into place and supported by governments and health insurance systems”

*Jean de Gunzberg, Da-Volterra*



Da-Volterra Superbugs 2017



Superbugs 2017 Featuring talks from FDA, GSK, BARDA + more

His [keynote address](#) will explore the consequences of antibiotic-induced dysbiosis, delve further into pharmacological interventions targeting the gut microbiome, and offer progressive insight into microbiodata-derived products aimed at *C. difficile* infections.

When asked about the threat of AMR, Jean said:

"The threat of antimicrobial resistance is even more serious than in the previous years: antimicrobial stewardship in developed countries has not made much progress, while uncontrolled antimicrobial use and the lack of containment strategies for resistant organisms in many developing

countries, such as waste water management (sewage), are enabling the level of resistance to continue increasing."

"Economic initiatives ensuring that such R&D projects are sustainable for pharma must be put into place and supported by governments and health insurance systems"

Da Volterra will be joining other notable speakers at Superbugs & Superdrugs 2017 including the FDA, TranScrip, Chemical Biology Ventures, BARDA, GlaxoSmithKline, Spero Therapeutics and Discuva.

Further information including a full speaker line-up is available at [www.superbugssuperdrugs.com](http://www.superbugssuperdrugs.com)

Superbugs & Superdrugs 2017  
20TH & 21ST March  
Cophorne Tara Hotel, London, UK  
Sponsored by MSD and Synthetic Biologics, Inc

--end --

#### Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: [tarri@smi-online.co.uk](mailto:tarri@smi-online.co.uk)  
For delegate enquires contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: [fbegum@smi-online.co.uk](mailto:fbegum@smi-online.co.uk)  
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

#### About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri  
SMi Group  
+442078276162  
email us here

SMi's 19th Annual Event... 

# Superbugs & Superdrugs

Cophorne Tara Hotel  
London, UK

20TH - 21ST  
MARCH  
2017

[www.superbugssuperdrugs.com](http://www.superbugssuperdrugs.com)

Superbugs and Superdrugs 2017

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.  
© 1995-2017 IPD Group, Inc. All Right Reserved.